VIlnius University Hospital

The trials here

What the 15 trials at this site are about, from their registry records.

Conditions

• Atrial fibrillation2 trials
• Acute lymphoblastic leukaemia1 trial
• Ankylosing spondylitis1 trial
• Childhood cancers1 trial
• Coronary artery disease1 trial
• Endometrial cancer1 trial
• Hidradenitis suppurativa1 trial
• High blood pressure1 trial
• Lung cancer1 trial
• Multiple myeloma1 trial
• Myelodysplastic syndromes1 trial
• Prostate cancer1 trial
• and 4 more

Phase

• Phase 38 trials
• Phase 22 trials
• Phase 2/32 trials
• Phase 1/21 trial

Status

• Completed8 trials
• Active, not recruiting6 trials
• Recruiting1 trial

Lead sponsor

• Janssen Research & Development, LLC3 trials
• AbbVie1 trial
• Actelion1 trial
• Alfasigma S.p.A.1 trial
• Bayer1 trial
• and 8 more

Running trials

• Active, not recruiting

  DART (19-14434) Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study investigating PDL1 positive and negative patients

  NCT04392504· Phase 1/2· Oslo University Hospital Hf· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Safety and Performance of the SpherePVI™ Catheter to Treat Paroxysmal Atrial Fibrillation

  NCT05144503· Medtronic Cardiac Ablation Solutions· Source

  Contact: Gediminas Račkauskas, MD. PhD

• Recruiting

  A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

  NCT03911128· Mats Heyman· Source

  Contact: Trial Central Office

• Active, not recruiting

  A Phase 3 study to see the benefit and safety of Luspatercept in comparison with Epoetin Alfa to treat anaemia due to very low, low or intermediate risk Myelodysplastic Syndromes (MDS) in people who have not taken erythropoiesis-stimulating agents (ESA's) before and who require red blood cell transfusions.

  2022-501485-22-00· Phase 3· Celgene Corp.· Source

• Active, not recruiting

  Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients

  NCT03376672· Phase 2· Raija Silvennoinen· Source

• Active, not recruiting

  A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

  NCT02629159· Phase 3· AbbVie· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atrial fibrillation1 recruiting

Closed trials

• Completed

  Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

  2022-502196-31-00· Phase 2/3· Kartos Therapeutics Inc.· Source

• Completed

  Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

  NCT05819398· Phase 2/3· Boehringer Ingelheim· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

  NCT05785611· Phase 3· Alfasigma S.p.A.· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC

  NCT05611671· Phase 2· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Source

• Completed

  Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer

  NCT04736199· Phase 3· Bayer· Source

• Active, not recruiting

  A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

  NCT04175600· Phase 3· Actelion· Source